While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

“The first thing they see is the loose skin on their abdomen," says R. Brannon Claytor, a Bryn Mawr, Pa.-based plastic ...

Jim Cramer, the host of Mad Money, recently took a deep dive into the challenges facing the consumer packaged goods sector, ...

WVU medicine is conducting a trial to combat weight gain after patients stop taking GLP-1 drugs such as Ozempic. Officials ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...